Nucleome Therapeutics
Generated by Meeveem AI
"Decoding the regulatory genome to discover precision medicines for inflammatory diseases"
Oxford
•51 - 250 Employees
•Clinical Systems
About Nucleome Therapeutics
Nucleome uses 3D genomics to discover precision medicines for inflammatory diseases. The company decodes the regulatory genome, linking disease associated genetic variants to the genes they dysregulate. This enables identification of novel drug targets and mechanisms invisible to traditional approaches, addressing rheumatoid arthritis, lupus, and inflammatory bowel disease. Working backwards from disease genetics to target, Nucleome builds a data atlas of immune dysregulation. By understanding how variants alter gene regulation in specific cell types, the company identifies causal genes driving inflammation. These genetically validated targets feed a pipeline of first in class therapeutics designed to restore immune homeostasis.
Illustrative visual - may not reflect the actual offering.
Illustrative visual - may not reflect the actual offering.
52
Team Members
2019
Founded
Clinical Systems
Sector
Hybrid
Work Environment
Our Vision
A world where molecular drivers of inflammatory disease are fully understood, enabling treatments that address root causes rather than symptoms, restoring immune balance and transforming lives through genetically guided precision medicine.
Our Mission
At Nucleome, our mission is to unlock the regulatory genome to reveal the molecular drivers of immune mediated disease using the precision and scale of our 3D genomics technology, to forge a new era of transformative therapeutics.